Výsledky vyhledávání - "Bernard Paule"

Akademický článek

Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.

Autor: Bernard Paule, Laurence Bastien, Emmanuelle Deslandes, Olivier Cussenot, Marie-Pierre Podgorniak, Yves Allory, Benyoussef Naïmi, Raphael Porcher, Alexandre de La Taille, Suzanne Menashi, Fabien Calvo, Samia Mourah

Publikováno v: PLoS ONE, Vol 5, Iss 5, p e10715 (2010)

Angiogenesis is the target of several agents in the treatment of malignancies, including renal cell carcinoma (RCC). There is a real need for surrogate biomarkers that can predict selection of patients who may benefit from antiangiogenic therapies, p

Externí odkaz: https://doaj.org/article/e6de44b3d3ef40fc8740133a48fbc969

Zobrazit plný text záznamu

Akademický článek

Adjuvant Gemcitabine-Oxaliplatin (GeMOX) after Curative Surgery in High-risk Patients with Cholangiocarcinoma

Autor: Bernard Paule, Paola Andreani, Marie-Pierre Bralet, Catherine Guettier, René Adam, Denis Castaing, Daniel Azoulay

Publikováno v: Clinical Medicine Insights: Oncology, Vol 3 (2009)

Background There is no standard adjuvant chemotherapy to prevent recurrent cholangiocarcinoma (CCA), a rare cancer with poor prognosis. We assessed the efficacy and safety of GEMOX on intrahepatic and hilar CCA with high-risk factors after curative s

Externí odkaz: https://doaj.org/article/94d483fb5b5245d78964b06b7aff94a6

Zobrazit plný text záznamu

Supplementary Figure 1 from Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy

Autor: Alexandre de la Taille, Francis Vacherot, Ralph Buttyan, Stéphane Culine, Laurent Salomon, Bernard Paule, Estelle Coppolani, Nathalie Nicolaiew, Pascale Soyeux, Laurence Kheuang, Nanor Sirab, Yves Allory, Pascale Maillé, Stéphane Terry, Guillaume Ploussard

Supplementary Figure 1 from Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ac45cb335ebda3c99b1da79e28e6cd4
https://doi.org/10.1158/0008-5472.22386840

Zobrazit plný text záznamu

Supplementary Table 1 from Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy

Supplementary Table 1 from Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63789625a8aed179acab1ae562408f18
https://doi.org/10.1158/0008-5472.22386819.v1

Zobrazit plný text záznamu

Supplementary Figure 5 from Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy

Supplementary Figure 5 from Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36251feb7f06b86db0e969d055bbaae7
https://doi.org/10.1158/0008-5472.22386828

Zobrazit plný text záznamu

Supplementary Figure 3 from Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy

Supplementary Figure 3 from Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c84870fbf8aeac6ae63c9d675fd43ed0
https://doi.org/10.1158/0008-5472.22386834.v1

Zobrazit plný text záznamu

Supplementary Methods from Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy

Supplementary Methods from Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8649e239e042d1d64f5dcdda11f25614
https://doi.org/10.1158/0008-5472.22386822.v1

Zobrazit plný text záznamu

Supplementary Figure Legends 1-5 from Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy

Supplementary Figure Legends 1-5 from Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22d83ce067fa17533b0205fb4dadfe99
https://doi.org/10.1158/0008-5472.22386825

Zobrazit plný text záznamu

Supplementary Figure 2 from Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy

Supplementary Figure 2 from Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38a5943f3a93709659eed3793a8b9ac6
https://doi.org/10.1158/0008-5472.22386837

Zobrazit plný text záznamu

Renal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 study

Autor: Eric Terrebonne, Hedia Brixi, Bernard Paule, Karine Le Malicot, Côme Lepage, Jean-Louis Legoux, Abakar Mahamat-Abakar, Thierry Lecomte, Pierre-Luc Etienne, Catherine Lombard-Bohas, Gabriel Choukroun, Sophie Dominguez, Philippe Ruszniewski, Pierre Michel, François-Xavier Caroli-Bosc, for Streptotox-FFCD investigators, Laetitia Dahan

Publikováno v: Clinics and Research in Hepatology and Gastroenterology
Clinics and Research in Hepatology and Gastroenterology, 2021, 45 (5), pp.101572. ⟨10.1016/j.clinre.2020.10.014⟩
Clinics and Research in Hepatology and Gastroenterology, Elsevier, 2021, 45 (5), pp.101572. ⟨10.1016/j.clinre.2020.10.014⟩

Introduction Streptozocin can impair renal function. The purpose of this study was to evaluate the evolution of renal function in patients receiving this anti-mitotic for the treatment of locally advanced/metastatic digestive well differentiated neur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e4ef5251bf40921ddc568e32623a457
https://univ-angers.hal.science/hal-03284389

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání